First Clinical Trial Under Novartis' Beacon of Hope Set to Launch
The first clinical trial under Novartis’s 10-year, multimillion dollar Beacon of Hope collaboration with 26 Historically Black Colleges is set to launch at Morehouse School of Medicine.
Morehouse is the first institution to establish a clinical trial center of excellence under the Beacon of Hope program, which seeks to address systemic health disparities across the research and medical development ecosystem and increase diversity in clinical trial participants and investigators.
The Morehouse Center’s first clinical trial is in LDL-C management, key to addressing a high coronary heart disease mortality rate among African Americans.
Read more about the trial and expansion here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
